🇺🇸 FDA
Patent

US 10322168

High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same

granted A61KA61K38/28A61K9/0073

Quick answer

US patent 10322168 (High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same) held by Amphastar Pharmaceuticals, Inc. expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Amphastar Pharmaceuticals, Inc.
Grant date
Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K38/28, A61K9/0073, A61K9/008, A61K9/143